AMP®AIM is a collaboration of experts from a range of scientific disciplines working together to expand researchers understanding of the cellular and molecular interactions that lead to inflammation and autoimmune disease.
BACKGROUND
The Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Disease Program (AMP AIM) was launched in 2021 as a collaboration between the National Institutes of Health (NIH), the Foundation for the National Institutes of Health (FNIH), pharmaceutical companies, and nonprofit organizations. AMP AIM researchers focus on psoriatic spectrum disorder (PSD), rheumatoid arthritis (RA), Sjögren’s disease (SjD), and systemic lupus erythematosus (SLE).
AMP AIM Team Science Leadership Scholars Program (LSP)
The LSP is a joint initiative that aligns the National Institute of Arthritis and Musculoskeletal and Skin Diseases’ (NIAMS) goal of supporting team science and collaboration with the Office of Data Science Strategy (ODSS) and the Office of Research on Women’s Health’s (ORWH) vision of preparing leaders in women’s health research. In this respect, AMP AIM provides the necessary structure and expanse to advance leadership and mentoring skills of promising researchers committed to working within a large network of stakeholders. The goal of the LSP is to prepare next generation leaders of team science that will improve women’s health.
LSP Program Scope and Components
This program focuses on positively impacting advancement of female scientists to team science and institutional leadership positions. This program will provide salary support and protected time to develop leadership and team science skills for promising mid-career scientists committed to research to advance women’s health. The program aims to fund 3 to 4 applicants focused on research of female-dominant autoimmune or immune-mediated diseases.